Skip to main content
. 2021 Aug 6;22(16):8481. doi: 10.3390/ijms22168481

Figure 5.

Figure 5

Diagnostic and prognostic value of YY1 and BCL2L15 in CRC patients’ cohorts. (A) GSE28702, dot plots with median of YY1 2log expression in CRC samples primary and metastasis. (B) GSE28702, Fisher’s exact test, data represented as YY1 low vs. high percentage expression in CRC samples, primary vs. metastasis. (C) GSE28702, receiver operating characteristics (ROC) analysis of YY1 expression in CRC samples primary vs. metastasis. (D) GSE28702, dot plots with median of BCL2L15 2log expression in CRC samples primary and metastasis. (E) GSE28702, Fisher’s exact test, data represented as BCL2L15 low vs. high percentage expression in CRC samples primary vs. metastasis. (F) GSE28702, ROC analysis of BCL2L15 expression in CRC samples primary vs. metastasis. (G) GSE14333, Kaplan–Meier analysis of relapse-free survival correlated with YY1 expression (high:low = 30%:70%). (H) GSE14333, Kaplan–Meier analysis of relapse-free survival correlated with BCL2L15 expression (high:low = 30%:70%). * p < 0.05; ** p  <  0.01.